Hikma Pharmaceuticals Share Price (HIK)
| Bid price | 629.50 | Open price | 625.00 |
|---|---|---|---|
| Ask price | 631.00 | Prev close | 629.50 |
| High price | 632.50 | Spread | 0.24% |
| Low price | 619.00 | Volume | 228,954 |
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades and FREE Hikma Pharmaceuticals company fundamentals, market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Hikma Pharmaceuticals Share Price Chart
Register now for FREE Hikma Pharmaceuticals share price charts
Hikma Pharmaceuticals Share Price Information
| Name | Hikma Pharmaceuticals | Epic | HIK |
|---|---|---|---|
| Activites | Branded accounted for 55% of 2008 revenues; Injectables, 26%; Generics, 18% and Other, 1% | Reuters | HIK.L |
| ISIN | GB00B0LCW083 | Google Finance | LON:HIK |
| Share Price (p) | 629.50 | Prev. Share Price (p) | 629.50 |
|---|---|---|---|
| Shares in Issue (m) | 197 | Market Cap (£m) | 1,227 |
| PE Ratio (x) | 24.16 | Div per share (p) | 4.80 |
| Div yield (%) | 1.29 | Div cover (x) | 3.18 |
| EPS (p) | 25.70 | PEG | 1.34 |
Register now for FREE Hikma Pharmaceuticals company fundamentals
Hikma Pharmaceuticals Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 19/03/2012 | EXR | Mazen Darwazeh | ED | 69,000 |
| 19/03/2012 | EXR | Said Darwazah | CEO | 115,000 |
| 18/10/2011 | EXR | Said Darwazah | CEO | 90,000 |
| 18/10/2011 | BUY | Ronald Goode | NED | 8,000 |
| 18/10/2011 | BUY | Ronald Goode | NED | 8,000 |
Hikma Pharmaceuticals Company News
Director/PDMR Shareholding
/* */ RNS Number : 6560D Hikma Pharmaceuticals Plc 18 May 2012 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 18 May 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that, further to the approval of the...
Result of AGM
/* */ RNS Number : 6022D Hikma Pharmaceuticals Plc 17 May 2012 Hikma Pharmaceuticals PLC Results of 2012 Annual General Meeting LONDON, 17 May 2012 - Hikma Pharmaceuticals PLC ("the Company") advises that at its Annual General Meeting of...
Hikma Pharmaceuticals maintains guidance
Hikma Pharmaceuticals is maintaining its 2012 guidance for revenue growth of around 20%. The group's branded business grew by 28% in the first four months of the year, with 12% organic revenue growth. And it says two of its largest markets, Algeria and Egypt, are delivering excellent growth,...
More Hikma Pharmaceuticals Company News >>
Register now for FREE Hikma Pharmaceuticals company news
Hikma Pharmaceuticals Share Price Discussions
Hikma Pharmaceuticals (HIK)
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions